Abstract
As a novel post-translational modification of proteins, succinylation is widely present in both prokaryotes and eukaryotes. By regulating protein translocation and activity, particularly involved in regulation of gene expression, succinylation actively participates in diverse biological processes such as cell proliferation, differentiation and metabolism. Dysregulation of succinylation is closely related to many diseases. Consequently, it has increasingly attracted attention from basic and clinical researchers. For a thorough understanding of succinylation dysregulation and its implications for disease development, such as inflammation, tumors, cardiovascular and neurological diseases, this paper provides a comprehensive review of the research progress on abnormal succinylation. This understanding of association of dysregulation of succinylation with pathological processes will provide valuable directions for disease prevention/treatment strategies as well as drug development.
1 Introduction
Protein posttranslational modification (PTM) encompasses the covalent processing that proteins undergo after translation, involving many biological processes (Wu et al., 2022). At present, the most common PTMs are phosphorylation, acetylation and succinylation, etc (Mu et al., 2021).
Lysine succinylation (Ksucc) is a new, broad-spectrum, dynamic, reversible PTM that has been discovered in recent years (Figure 1) (Zhang H. et al., 2023). It is involved in almost all biological processes of organisms (Ye and Li, 2022), playing an important role in the metabolic regulation, signal transduction and cell differentiations (Amirkashani et al., 2023; Huang et al., 2023), mainly through the regulation of protease activity and gene expression (Huang et al., 2021). The regulation of succinylation and involves multiple factors, including succinyl-donor and the regulators of succinylation (Lu and Han, 2022). Dysregulation of succinylation, changing activity and aberrant function of protein involved in energy metabolism and downstream epigenetic modification (Chinopoulos, 2021), is closely related to the occurrence and development of diseases such as inflammation, tumors and others (Zhang et al., 2022). In this review, we intend to discuss the occurrence of succinylation dysregulation, including the characteristics, distribution and mechanism of the dysregulation. Meanwhile, we will summarize the theoretical and experimental evidence of succinylation dysregulation in various diseases, triggering further research on succinylation as a future therapeutic target for diseases.
FIGURE 1
Reversible modification of lysine succinylation and its regulatory factors.
2 Occurrence of succinylation
Succinylation is a process by which a negatively charged four-carbon succinyl group is covalently bound to the primary amine of lysine residue by enzymatic or non-enzymatic means (Ali et al., 2020). It leads to significant changes in protein structure due to the large spatial structure of the succinyl group, as well as a change in charge from +1 to −1 for the lysine residue, resulting in alterations in physicochemical properties and biological functions of proteins (Dai et al., 2022). Succinylases such as CPT1A and KAT2A are required in enzymatic succinylation, but sufficient succinyl-CoA supply is a pre-request for the occurrence of non-enzymic succinylation (Mu et al., 2021).
Succinylation is widely distributed in mitochondria and sub-cells (Zhang H. et al., 2023). In mitochondria, the abundance of succinyl-CoA is one of the main governing factors of Ksucc. The TCA cycle generates large amounts of succinyl-CoA, which may contribute to passive succinylation (Sreedhar et al., 2020). Secondly, an electrostatic attraction between succinyl CoA and lysine residues may play an auxiliary, but the detail mechanisms remained further study. Succinylation can be involved in differentiation, metabolism and other important life processing by regulating protease activity and gene expression (Ye and Li, 2022). This makes succinylation highly valuable for the study of diseases related to mitochondrial disorders (Yang Y. H. et al., 2022). For example, succinylation at K311 of glutaminase (GLS-K311succ) enhances its activity, offsetting oxidative stress while promoting tumor cell survival and growth pancreatic ductal adenocarcinoma (PDAC) (Tong et al., 2021). In nucleus, succinylation is present in over one-third of nucleosomes (histone/non-histone). H3-K79succ leads to increased β-catenin stability and subsequently promotes gene expression of cyclin D1, c-Myc, GLUT1 and lactate dehydrogenase A (LDHA) in tumorigenesis (Wang et al., 2018). FEN1 K77succ reduced the accumulation of DNA damage and sensitivity to fork stalling agents through enhancing its bond with Rad9-Rad1-Hus1 (Shi et al., 2020). Succinylation directly regulates genome-wide transcription and DNA repair activity through chromatin remodeling (Zorro Shahidian et al., 2021).
3 Regulation and dysregulation of succinylation
Normally, succinylation is strictly regulated by the succinyl-donor, succinylases, and desuccinylase (Lu and Han, 2022). Changes of the concentration of succinyl-donors and activity of enzymes can cause dysregulation of succinylation (Lu et al., 2021).
3.1 Influence of the succinyl-donor on succinylation
Succinyl-CoA serves as the primary donor for succinylation, and its concentration reversibly regulates the process of succinylation (Chinopoulos, 2021). Overall decrease in the mitochondrial succinyl-CoA pool, decreased myofibril protein succinylation, which may promote heart failure (Ali et al., 2020). Succinyl-CoA deficiency, impeding ketone oxidation in skeletal muscle, is often associated with acute episodes of ketoacidosis (Mechchate et al., 2023). Enzymes affecting succinyl-CoA production indirectly regulate succinylation levels. For instance, α-ketoglutaric dehydrogenase (α-KGDH) promotes succinylation by increased succinyl-CoA produced in propionate and/or ketone body metabolism in nerve cell, accelerating progression of neurodegenerative diseases (Dobolyi et al., 2020).
Additionally, succinate or other metabolites can also impact the extent of succinylation (Guillon et al., 2022). Accumulation of ischemic succinate increased the succinylation of the Rho family GTPase Cdc42, resulting in neural stem cell proliferation inhibition and aggravated cerebral ischemia/reperfusion (I/R) injury (Huang et al., 2023). Therefore, targeting on succinylation is considered as a potential therapeutic approach for I/R (Liu et al., 2020).
3.2 Effects of succinylases on succinylation
In recent years, significant progresses have been made in the study of succinylases, with the identification of several new succinylases, such as lysine acyltransferase 2A (KAT2A), and carnitine palmitoyltransferase 1A (CPT1A) (Lu et al., 2021).
KAT2A is also known as General Control Non-derepressible 5 (GCN5), whose histone succinylases activity plays a crucial role in tumorigenesis (Tong et al., 2020). KAT2A-mediated H3-K79succ regulates gene expression and β-catenin stability in tumor cells, contributing to tumor cell proliferation and invasion (Tong et al., 2021). In prostate cancer (PCa) cells, KAT2A-mediated CTBP- K46 and K280succ can repress transcription suppressing activity of it, thus acting as an oncogene (Zhou et al., 2023).
CPT1A has also been identified as a potential succinylases. In gastric cancer (GC), CPT1A-mediated LDHA-K222succ reduces its binding to SQSTM1 and inhibits the degradation of LDHA, as well as promotes GC invasion and proliferation.
3.3 Effects of desuccinylases on succinylation level
Sirtuin5(SIRT5) possess NAD+-dependent desuccinylation activity (Green and Storey, 2021; Zhang and Goetzman, 2021), reducing succinylation levels of mitochondrial proteins (Chinopoulos, 2021), and subsequently modulating the target activities of numerous substrate proteins to maintain metabolic homeostasis (Lukey et al., 2020). SIRT5 protein reduces LDHA-K118succ in PCa, by which it may be used as a new strategy to prevent the progression of castration-resistant PCa for treatment (Kwon et al., 2023). SIRT5 can inhibit peroxisom-induced oxidative stress, liver protection and inhibit the development of hepatocellular carcinoma by reducing the succinylation level of peroxisomal ACOX1 (Chen et al., 2018). Consequently, SIRT5 is considered a pivotal regulator in various cancers and inhibitors targeted succinylation may serve as promising anti-tumor (Shen et al., 2023).
Additionally, it has been discovered that SIRT7 possesses desuccinylase activity, primarily in nucleus (Bai et al., 2022). It serves important functions such as stimulating the expression of ribosomal RNA, facilitating DNA damage repair, and balancing chromatin compaction (Lagunas-Rangel, 2023). These findings emphasize the critical role of SIRT7 in protecting chromatin structure, controlling innate immune regulation and ensuring reproductive protection during stem cell senescence (Raza et al., 2024).
4 Dysregulation of succinylation and diseases
Dysregulation of succinylation plays a crucial role in the occurrence and progression of diseases since activity/sublocation of disease-related proteins or key enzymes are changed (Dai et al., 2022). Therefore, the relationship between dysregulation of succinylation and diseases can provide theoretical support for disease treatment and related drugs (Liu et al., 2022) (Table 1).
TABLE 1
| Diseases | Ksucc proteins | Ksucc sites | Influence | Regulatory factors | References | |
|---|---|---|---|---|---|---|
| Inflammation and Tuberculosis | fungal infections | Aconitase in S. erythraea HL3168 E3 | K278 | Inhibit metabolism in the host | erythromycin | Ke et al. (2022) |
| K373 | ||||||
| Tuberculosis | EchA19 in Mtb | K132 | succinyl-CoA | Bonds et al. (2020) | ||
| K139 | ||||||
| Hepatitis B | histone H3 | K79 | Promote the replication of HBV | GCN5 | Yuan et al. (2020b) | |
| influenza pneumonia | Nucleoprotein influenza virus | K87 | Disrupt the influenza replication cycle | succinate | Guillon et al. (2022) | |
| Tumor | PDAC | histone H3 | K79 K311 | promote proliferation, migration and invasion of tumor cells | KAT2A SIRT3-5 | (Tong et al., 2020; Tong et al., 2021) |
| GLS | ||||||
| HCC | PGAM1 | K99 | Aspirin | Wang et al. (2023) | ||
| hRIDA | K293 | SIRT5 | Siculella et al. (2021) | |||
| GC | S100A10 | K47 | CPT1A | Wang et al. (2022) | ||
| FBN1 | k672 | Li et al. (2020) | ||||
| LDHA | K222 | |||||
| gliomas | TAGLN2 | K40 | — | Zhang et al. (2023b) | ||
| PCa | CTBP1 | K46 | KAT2A | Zhou et al. (2023) | ||
| K280 | ||||||
| LDHA | K118 | SIRT5 | Kwon et al. (2023) | |||
| colon cancer | CS | K393 | Inhibit the proliferation and migration of cancer cells | Ren et al. (2020) | ||
| K395 | ||||||
| breast cancer and lung cancer | GLS | K164 | Lukey et al. (2020) | |||
| K311 | ||||||
| K158 | ||||||
| cardiovascular diseases | hypertrophic cardiomyopathy | ECHA | — | promote myocardial fibrosis, reduce cardiac function | SIRT5 | Sadhukhan et al. (2016) |
| heart failure | IDH2 | Chang et al. (2021) | ||||
| TAA、TAD | PKM、LDHA、SDHA | Zhang et al. (2023a) | ||||
| neurological diseases | AD | APP and tau protein | — | promote the development of AD | SIRT5 | Yang et al. (2022b) |
| I/R | GTPase Cdc42 | aggravate cerebral I/R injury | Huang et al. (2023) | |||
| anxiety | PDHC | decrease parasympathetic activity and anxiety indicators | Artiukhov et al. (2022) | |||
Locations, influence and regulatory factors of Ksucc proteins in diseases.
4.1 Dysregulation of succinylation and inflammation/tuberculosis
As mentioned above, protein succinylation, as a conservative PTM, participates in diverse biological processes in bacteria, fungi, viruses and human cells (Yuan T. et al., 2020).
Succinylation plays an important role in protein biosynthesis and carbon metabolism of bacteria/fungi and antibiotic biosynthesis. The succinylation levels of vancomycin-intermediate Staphylococcus aureus (VISA) decreased with enhanced vancomycin tolerance (Yang et al., 2024). EchA19-K132, 139succ in Mycobacterium tuberculosis (Mtb) is a negative feedback regulator of cholesterol metabolism in the host (Bonds et al., 2020). In addition, increased succinylation exerting favorable inhibition of Aspergillus fumigatus infection in terms of fungicidal and enhanced macrophage killing effect (Chen et al., 2023). These findings provide valuable insights into the mechanism of desuccinylase inhibitors in the treatment of ITR-resistant fungal infections.
Succinylation dysregulation may play a critical role in viral infection. SARS-CoV-2, the pathogen responsible for the COVID-19 pandemic, induces succinylation of several crucial enzymes in the tricarboxylic acid cycle (TCA), leading to inhibition of cellular metabolic pathways (Liu et al., 2022). Notably, IFN-α clears hepatitis B virus (HBV) cccDNA through depressed GCN5-mediated H3-K79succ (Yuan Y. et al., 2020). Therefore, inhibitors targeting succinylation exhibit significant antiviral effects, providing provide a new avenue for anti-viral treatment.
4.2 Dysregulation of succinylation and immunity/tumor
Dysregulation of succinylation affects the infiltration of immune cells and the expression of immune genes, thereby promoting the malignant development of cancer (Lu et al., 2021). Succinylation induces the expression of pro-inflammatory genes in T cells and activates HIFα in M1 macrophages, leading to the inflammation-cancer cycle (Shen et al., 2023).
Succinylation is tissue heterogeneous during tumorigenesis (Lu and Han, 2022), and it is involved in the regulation of various tumorigenesis and progression through different substrate targets or signaling pathways (Zhang X. et al., 2023).
In general, succinylation can have a pro-cancer effect. It is significantly high-expressed in various tumor tissues such as lung cancer, PCa, HCC, PDAC and glioma (Zhang X. et al., 2023; Zhou et al., 2023). Elevated succinylation is closely related to tumor invasion/metastasis ability and patient survival prognosis (Lukey et al., 2020). There are two mechanisms for the pro-cancer effect of succinylation. One involves inhibiting degradation of succinylated substrate, thus promoting proliferation, invasion and migration of tumor cells. Upregulation of CPT1A and downregulation of SIRT5 synergistically promotes S100A10-K47succ and fibrillin 1 (FBN1) K672succ, resulting in the accumulation of S100A10 and FBN1 in GC cells and further promoting tumor progression (Wang et al., 2022). Another mechanism is that succinylation helps maintain the redox balance of cancer cells and promotes their proliferation. In colon cancer, elevated PKM2-K498succ promotes the production of more ATP during glucose starvation and maintains tumor cell survival during nutrient depletion (Qi et al., 2019).
It is paradoxical that high citrate synthase (CS) K393 and 395succ significantly inhibits the proliferation and migration of colon cancer cells (Ren et al., 2020), and the detection of increased SIRT5 expression levels in lung cancer and breast cancer (Lu and Han, 2022). This suggests that increased succinylation contributes to the suppression of certain tumors.
4.3 Dysregulation of succinylation in cardiovascular diseases
The concentration of succinyl-CoA in the heart tissue is significantly higher than that in any other organs. Succinylation is closely associated with cardiomyocyte metabolism and its dysregulation is widely involved in cardiovascular disease (CVD) (Weis et al., 2022). Highly succinated proteins highly enriched in thoracic aortic aneurysms (TAA) and thoracic aortic dissection (TAD) Promise to be potential diagnostic markers and therapeutic targets for aortic diseases (Zhang H. et al., 2023). Accumulation of succinylated ECHA leads to decreased ATP production in the myocardium, reduced cardiac ejection fraction, and ultimately to hypertrophic cardiomyopathy (Hershberger et al., 2018). During myocardial ischemia, SIRT5 significantly promotes the desuccinylation of IDH2, a key enzyme involved in TCA, maintaining mitochondrial homeostasis and improving myocardial fibrosis, reduce the incidence of heart failure (Chang et al., 2021).
4.4 Dysregulation of succinylation in neurological diseases
The analysis of succinylated proteomics data and transcriptomics data revealed that the mRNAs matched by most differentially succinylated proteins were especially highly expressed in neurons and astrocytes (Deng et al., 2021). Abnormal succinylation may be linked to abnormal cortical nerve anatomy and could potentially contribute to the pathological processes of various neurological disorders (Ning et al., 2022). In Alzheimer’s disease, increased succinylation level of amyloid precursor protein disrupts its normal proteolytic processing, leading to the accumulation of Aβ and plaque formation. Additionally, succinylation of tau protein promotes its aggregation into tangles and impairs microtubule assembly (Yang Y. et al., 2022). An elevated succinylation level of pyruvate dehydrogenase complex (PDHC) in the hippocampus may downregulate mitochondrial energy metabolism, while potentially contributing to parasympathetic activity dysregulation, anxiety and depression (Artiukhov et al., 2022). Therefore, studying the mechanism and function of desuccinylation can provide a foundation for targeted therapy of nervous system diseases.
4.5 Dysregulation of succinylation in other diseases
Dysregulation of succinylation is associated with reproductive disorders (Yang et al., 2018). Reduction of LDHC-K317succ reduces production of ATP, leading to asthenospermia (Yang et al., 2020). Inhibition succinylation of germ cell can result in reproductive injury. Analysis of postmenopausal women aged from 55 to 70 years old indicate that succinylation of apolipoprotein A-I and A-II, hemoglobin subunit α and haptoglobin are elevated in patients with osteoporosis and osteopenia (Zhang et al., 2019). This suggests that elevated succinylation is associated with aging and age-related diseases. (Du et al., 2018).
5 Perspective
It is well-known that succinylation and its dysregulation are closely related to the processes in cells, including variety of physiological and pathological processes. Although dysregulation of succinylation has been extensively investigated in regulation of metabolism and epigenetics, the factors underlying variations in succinylation levels across different tumors or other conditions remain to be fully elucidated. It is necessary for scientists to identify accurate roles of succinylases and succinyl-CoA in executing succinylation on different molecules, distinguishing active and passive modification of succinylation.
As for disease, succinylation modification is mainly involved in metabolism regulation, particularly in energy production, thus obesity and type II diabetes are most likely to relate to dysregulation of succinylation. Further and extensive investigations are required to explore its roles and accurate mechanism in trigger those diseases. In addition, a variety of PTMs usually act in combination, such as high overlap between succinylation and acetylation (Ye and Li, 2022), and the interaction between them also needs to be further researched. It is apparent that there could be competition among various modifications occurring on the lysine residue, given that lysine is the most frequently modified residue in post-translational modifications.
Along with the development of proteomics research with mass spectrum technology, the in-depth study of the above issues will help us more accurately understand the relationship of succinylation dysregulation and disease development, and provide a theoretical foundation for treatment of the diseases and the development of related drugs.
Statements
Author contributions
XH: Conceptualization, Data curation, Formal Analysis, Validation, Writing–original draft. LZ: Data curation, Project administration, Visualization, Writing–review and editing. HX: Data curation, Formal Analysis, Project administration, Resources, Supervision, Writing–original draft. JS: Formal Analysis, Methodology, Supervision, Writing–review and editing. SJ: Conceptualization, Formal Analysis, Funding acquisition, Project administration, Resources, Supervision, Validation, Writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work is supported by the National Natural Science Foundation of China (No. 31371386. SJ).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Ali H. R. Michel C. R. Lin Y. H. McKinsey T. A. Jeong M. Y. Ambardekar A. V. et al (2020). Defining decreased protein succinylation of failing human cardiac myofibrils in ischemic cardiomyopathy. J. Mol. Cell Cardiol.138, 304–317. 10.1016/j.yjmcc.2019.11.159
2
Amirkashani D. Asadollahi M. Hosseini R. Talebi S. Golchehre Z. Keramatipour M. (2023). A novel mutation in the OXCT1 gene causing succinyl-CoA:3-ketoacid CoA transferase (SCOT) deficiency starting with neurologic manifestations. Iran. J. Child. Neurol.17 (2), 127–133. 10.22037/ijcn.v17i2.35963
3
Artiukhov A. V. Aleshin V. A. Karlina I. S. Kazantsev A. V. Sibiryakina D. A. Ksenofontov A. L. et al (2022). Phosphonate inhibitors of pyruvate dehydrogenase perturb homeostasis of amino acids and protein succinylation in the brain. Int. J. Mol. Sci.23 (21), 13186. 10.3390/ijms232113186
4
Bai W. Cheng L. Xiong L. Wang M. Liu H. Yu K. et al (2022). Protein succinylation associated with the progress of hepatocellular carcinoma. J. Cell Mol. Med.26 (22), 5702–5712. 10.1111/jcmm.17507
5
Bonds A. C. Yuan T. Werman J. M. Jang J. Lu R. Nesbitt N. M. et al (2020). Post-translational succinylation of Mycobacterium tuberculosis enoyl-CoA hydratase EchA19 slows catalytic hydration of cholesterol catabolite 3-Oxo-chol-4,22-diene-24-oyl-CoA. ACS Infect. Dis.6 (8), 2214–2224. 10.1021/acsinfecdis.0c00329
6
Chang X. Zhang T. Wang J. Liu Y. Yan P. Meng Q. et al (2021). SIRT5-Related desuccinylation modification contributes to quercetin-induced protection against heart failure and high-glucose-prompted cardiomyocytes injured through regulation of mitochondrial quality surveillance. Oxidative Med. Cell. Longev.2021, 5876841. 10.1155/2021/5876841
7
Chen X. Lei W. Meng H. Jiang Y. Zhang S. Chen H. et al (2023). Succinylation modification provides new insights for the treatment of immunocompromised individuals with drug-resistant Aspergillus fumigatus infection. Front. Immunol.14, 1161642. 10.3389/fimmu.2023.1161642
8
Chen X. F. Tian M. X. Sun R. Q. Zhang M. L. Zhou L. S. Jin L. et al (2018). SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep.19 (5), e45124. 10.15252/embr.201745124
9
Chinopoulos C. (2021). The mystery of extramitochondrial proteins lysine succinylation. Int. J. Mol. Sci.22 (11), 6085. 10.3390/ijms22116085
10
Dai X. Zhou Y. Han F. Li J. (2022). Succinylation and redox status in cancer cells. Front. Oncol.12, 1081712. 10.3389/fonc.2022.1081712
11
Deng Y. H. Zhang X. X. Tao C. Y. Liang Y. J. Yuan J. Yang S. H. et al (2021). Succinylation profiles of brain injury after intracerebral hemorrhage. PLoS One16 (11), e0259798. 10.1371/journal.pone.0259798
12
Dobolyi A. Bago A. Palkovits M. Nemeria N. S. Jordan F. Doczi J. et al (2020). Exclusive neuronal detection of KGDHC-specific subunits in the adult human brain cortex despite pancellular protein lysine succinylation. Brain Struct. Funct.225 (2), 639–667. 10.1007/s00429-020-02026-5
13
Du Y. Hu H. Qu S. Wang J. Hua C. Zhang J. et al (2018). SIRT5 deacylates metabolism-related proteins and attenuates hepatic steatosis in ob/ob mice. EBioMedicine36, 347–357. 10.1016/j.ebiom.2018.09.037
14
Green S. R. Storey K. B. (2021). Skeletal muscle of torpid Richardson's ground squirrels (Urocitellus richardsonii) exhibits a less active form of citrate synthase associated with lowered lysine succinylation. Cryobiology101, 28–37. 10.1016/j.cryobiol.2021.06.006
15
Guillon A. Brea-Diakite D. Cezard A. Wacquiez A. Baranek T. Bourgeais J. et al (2022). Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein. EMBO J.41 (12), e108306. 10.15252/embj.2021108306
16
Hershberger K. A. Abraham D. M. Liu J. Locasale J. W. Grimsrud P. A. Hirschey M. D. (2018). Ablation of Sirtuin5 in the postnatal mouse heart results in protein succinylation and normal survival in response to chronic pressure overload. J. Biol. Chem.293 (27), 10630–10645. 10.1074/jbc.RA118.002187
17
Huang L. Y. Ma J. Y. Song J. X. Xu J. J. Hong R. Fan H. D. et al (2023). Ischemic accumulation of succinate induces Cdc42 succinylation and inhibits neural stem cell proliferation after cerebral ischemia/reperfusion. Neural Regen. Res.18 (5), 1040–1045. 10.4103/1673-5374.355821
18
Huang Z. He L. Sang W. Wang L. Huang Q. Lei C. (2021). Potential role of lysine succinylation in the response of moths to artificial light at night stress. Ecotoxicol. Environ. Saf.220, 112334. 10.1016/j.ecoenv.2021.112334
19
Ke X. Jiang X. Huang M. Tian X. Chu J. (2022). Engineering of succinyl-CoA metabolism in view of succinylation regulation to improve the erythromycin production. Appl. Microbiol. Biotechnol.106 (13-16), 5153–5165. 10.1007/s00253-022-12060-4
20
Kwon O. K. Bang I. H. Choi S. Y. Jeon J. M. Na A. Y. Gao Y. et al (2023). LDHA desuccinylase sirtuin 5 as A novel cancer metastatic stimulator in aggressive prostate cancer. Genomics Proteomics Bioinforma.21 (1), 177–189. 10.1016/j.gpb.2022.02.004
21
Lagunas-Rangel F. A. (2023). The dark side of SIRT7. Mol. Cell. Biochem. 10.1007/s11010-023-04869-y
22
Li X. Zhang C. Zhao T. Su Z. Li M. Hu J. et al (2020). Lysine-222 succinylation reduces lysosomal degradation of lactate dehydrogenase a and is increased in gastric cancer. J. Exp. Clin. Cancer Res.39 (1), 172. 10.1186/s13046-020-01681-0
23
Liu Q. Wang H. Zhang H. Sui L. Li L. Xu W. et al (2022). The global succinylation of SARS-CoV-2-infected host cells reveals drug targets. Proc. Natl. Acad. Sci. U. S. A.119 (30), e2123065119. 10.1073/pnas.2123065119
24
Liu X. Zhu C. Zha H. Tang J. Rong F. Chen X. et al (2020). SIRT5 impairs aggregation and activation of the signaling adaptor MAVS through catalyzing lysine desuccinylation. EMBO J.39 (11), e103285. 10.15252/embj.2019103285
25
Lu K. Han D. (2022). A review of the mechanism of succinylation in cancer. Medicine101 (45), e31493. 10.1097/MD.0000000000031493
26
Lu W. Che X. Qu X. Zheng C. Yang X. Bao B. et al (2021). Succinylation regulators promote clear cell renal cell carcinoma by immune regulation and RNA N6-methyladenosine methylation. Front. Cell Dev. Biol.9, 622198. 10.3389/fcell.2021.622198
27
Lukey M. J. Greene K. S. Cerione R. A. (2020). Lysine succinylation and SIRT5 couple nutritional status to glutamine catabolism. Mol. Cell. Oncol.7 (3), 1735284. 10.1080/23723556.2020.1735284
28
Mechchate H. Abdualkader A. M. Bernacchi J. B. Gopal K. Tabatabaei Dakhili S. A. Yang K. et al (2023). Defective muscle ketone body oxidation disrupts BCAA catabolism by altering mitochondrial branched-chain aminotransferase. Am. J. Physiol. Endocrinol. Metab.324 (5), E425–e436. 10.1152/ajpendo.00206.2022
29
Mu R. Ma Z. Lu C. Wang H. Cheng X. Tuo B. et al (2021). Role of succinylation modification in thyroid cancer and breast cancer. Am. J. Cancer Res.11 (10), 4683–4699.
30
Ning Q. Ma Z. Zhao X. Yin M. (2022). SSKM_Succ: a novel succinylation sites prediction method incorporating K-means clustering with a new semi-supervised learning algorithm. IEEE/ACM Trans. Comput. Biol. Bioinform19 (1), 643–652. 10.1109/TCBB.2020.3006144
31
Qi H. Ning X. Yu C. Ji X. Jin Y. McNutt M. A. et al (2019). Succinylation-dependent mitochondrial translocation of PKM2 promotes cell survival in response to nutritional stress. Cell Death Dis.10 (3), 170. 10.1038/s41419-018-1271-9
32
Raza U. Tang X. Liu Z. Liu B. (2024). SIRT7: the seventh key to unlocking the mystery of aging. Physiol. Rev.104 (1), 253–280. 10.1152/physrev.00044.2022
33
Ren M. Yang X. Bie J. Wang Z. Liu M. Li Y. et al (2020). Citrate synthase desuccinylation by SIRT5 promotes colon cancer cell proliferation and migration. Biol. Chem.401 (9), 1031–1039. 10.1515/hsz-2020-0118
34
Sadhukhan S. Liu X. Ryu D. Nelson O. D. Stupinski J. A. Li Z. et al (2016). Metabolomics-assisted proteomics identifies succinylation and SIRT5 as important regulators of cardiac function. Proc. Natl. Acad. Sci. U. S. A.113 (16), 4320–4325. 10.1073/pnas.1519858113
35
Shen R. Ruan H. Lin S. Liu B. Song H. Li L. et al (2023). Lysine succinylation, the metabolic bridge between cancer and immunity. Genes Dis.10 (6), 2470–2478. 10.1016/j.gendis.2022.10.028
36
Shi R. Wang Y. Gao Y. Xu X. Mao S. Xiao Y. et al (2020). Succinylation at a key residue of FEN1 is involved in the DNA damage response to maintain genome stability. Am. J. Physiol. Cell Physiol.319 (4), C657–C666. 10.1152/ajpcell.00137.2020
37
Siculella L. Giannotti L. Di Chiara Stanca B. Calcagnile M. Rochira A. Stanca E. et al (2021). Evidence for a negative correlation between human reactive enamine-imine intermediate deaminase A (rida) activity and cell proliferation rate: role of lysine succinylation of rida. Int. J. Mol. Sci.22 (8), 3804. 10.3390/ijms22083804
38
Sreedhar A. Wiese E. K. Hitosugi T. (2020). Enzymatic and metabolic regulation of lysine succinylation. Genes Dis.7 (2), 166–171. 10.1016/j.gendis.2019.09.011
39
Tong Y. Guo D. Lin S. H. Liang J. Yang D. Ma C. et al (2021). SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells. Mol. Cell81 (11), 2303–2316 e8. 10.1016/j.molcel.2021.04.002
40
Tong Y. Guo D. Yan D. Ma C. Shao F. Wang Y. et al (2020). KAT2A succinyltransferase activity-mediated 14-3-3ζ upregulation promotes β-catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells. Cancer Lett.469, 1–10. 10.1016/j.canlet.2019.09.015
41
Wang X. Shi X. Lu H. Zhang C. Li X. Zhang T. et al (2022). Succinylation inhibits the enzymatic hydrolysis of the extracellular matrix protein fibrillin 1 and promotes gastric cancer progression. Adv. Sci. (Weinh)9 (27), e2200546. 10.1002/advs.202200546
42
Wang Y. Guo Y. R. Xing D. Tao Y. J. Lu Z. (2018). Supramolecular assembly of KAT2A with succinyl-CoA for histone succinylation. Cell Discov.4, 47. 10.1038/s41421-018-0048-8
43
Wang Y. F. Zhao L. N. Geng Y. Yuan H. F. Hou C. Y. Zhang H. H. et al (2023). Aspirin modulates succinylation of PGAM1K99 to restrict the glycolysis through NF-κB/HAT1/PGAM1 signaling in liver cancer. Acta Pharmacol. Sin.44 (1), 211–220. 10.1038/s41401-022-00945-z
44
Weis E. M. Puchalska P. Nelson A. B. Taylor J. Moll I. Hasan S. S. et al (2022). Ketone body oxidation increases cardiac endothelial cell proliferation. EMBO Mol. Med.14 (4), e14753. 10.15252/emmm.202114753
45
Wu J. Li N. Huang X. Chen J. Jia Y. He Z. et al (2022). Proteomic quantification of lysine acetylation and succinylation profile alterations in lung adenocarcinomas of non-smoking females. Yonago Acta Med.65 (2), 132–147. 10.33160/yam.2022.05.006
46
Yang Q. Li P. Wen Y. Li S. Chen J. Liu X. et al (2018). Cadmium inhibits lysine acetylation and succinylation inducing testicular injury of mouse during development. Toxicol. Lett.291, 112–120. 10.1016/j.toxlet.2018.04.005
47
Yang Q. Liu X. Chen J. Wen Y. Liu H. Peng Z. et al (2020). Lead-mediated inhibition of lysine acetylation and succinylation causes reproductive injury of the mouse testis during development. Toxicol. Lett.318, 30–43. 10.1016/j.toxlet.2019.10.012
48
Yang Y. Tan L. He S. Hao B. Huang X. Zhou Y. et al (2024). Sub-MIC vancomycin enhances the antibiotic tolerance of vancomycin-intermediate Staphylococcus aureus through downregulation of protein succinylation. Microbiol. Res.282, 127635. 10.1016/j.micres.2024.127635
49
Yang Y. Tapias V. Acosta D. Xu H. Chen H. Bhawal R. et al (2022b). Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer's disease. Nat. Commun.13 (1), 159. 10.1038/s41467-021-27572-2
50
Yang Y. H. Wu S. F. Zhu Y. P. Yang J. T. Liu J. F. (2022a). Global profiling of lysine succinylation in human lungs. Proteomics22 (17), e2100381. 10.1002/pmic.202100381
51
Ye J. Li J. (2022). First analyses of lysine succinylation proteome and overlap between succinylation and acetylation in Solenopsis invicta Buren (Hymenoptera: formicidae). BMC Genomics23 (1), 61. 10.1186/s12864-021-08285-8
52
Yuan T. Keijer J. Guo A. H. Lombard D. B. de Boer V. C. J. (2020a). An optimized desuccinylase activity assay reveals a difference in desuccinylation activity between proliferative and differentiated cells. Sci. Rep.10 (1), 17030. 10.1038/s41598-020-72833-7
53
Yuan Y. Yuan H. Yang G. Yun H. Zhao M. Liu Z. et al (2020b). IFN-α confers epigenetic regulation of HBV cccDNA minichromosome by modulating GCN5-mediated succinylation of histone H3K79 to clear HBV cccDNA. Clin. Epigenetics12 (1), 135. 10.1186/s13148-020-00928-z
54
Zhang H. Zhang Y. Wang H. Yang P. Lu C. Liu Y. et al (2023a). Global proteomic analysis reveals lysine succinylation contributes to the pathogenesis of aortic aneurysm and dissection. J. Proteomics280, 104889. 10.1016/j.jprot.2023.104889
55
Zhang L. L. Li C. W. Liu K. Liu Z. Liang B. C. Yang Y. R. et al (2019). Discovery and identification of serum succinyl-proteome for postmenopausal women with osteoporosis and osteopenia. Orthop. Surg.11 (5), 784–793. 10.1111/os.12519
56
Zhang X. Han J. Fan D. Wang J. Lin X. Zhang H. et al (2023b). Lysine-40 succinylation of TAGLN2 induces glioma angiogenesis and tumor growth through regulating TMSB4X. Cancer Gene Ther.30 (1), 172–181. 10.1038/s41417-022-00534-6
57
Zhang Y. Goetzman E. (2021). The enzyme activity of mitochondrial trifunctional protein is not altered by lysine acetylation or lysine succinylation. PLoS One16 (10), e0256619. 10.1371/journal.pone.0256619
58
Zhang Z. Chen Y. Fang L. Zhao J. Deng S. (2022). The involvement of high succinylation modification in the development of prostate cancer. Front. Oncol.12, 1034605. 10.3389/fonc.2022.1034605
59
Zhou J. Yan X. Liu Y. Yang J. (2023). Succinylation of CTBP1 mediated by KAT2A suppresses its inhibitory activity on the transcription of CDH1 to promote the progression of prostate cancer. Biochem. Biophys. Res. Commun.650, 9–16. 10.1016/j.bbrc.2023.02.002
60
Zorro Shahidian L. Haas M. Le Gras S. Nitsch S. Mourão A. Geerlof A. et al (2021). Succinylation of H3K122 destabilizes nucleosomes and enhances transcription. EMBO Rep.22 (3), e51009. 10.15252/embr.202051009
Summary
Keywords
post-translational modification, succinylation, dysregulation, disease, succinylase
Citation
Hou X, Zhu L, Xu H, Shi J and Ji S (2024) Dysregulation of protein succinylation and disease development. Front. Mol. Biosci. 11:1407505. doi: 10.3389/fmolb.2024.1407505
Received
26 March 2024
Accepted
15 May 2024
Published
31 May 2024
Volume
11 - 2024
Edited by
Sandra Donnini, University of Siena, Italy
Reviewed by
Yana Cen, Virginia Commonwealth University, United States
Francisco O. Silva, University of Texas Southwestern Medical Center, United States
Updates
Copyright
© 2024 Hou, Zhu, Xu, Shi and Ji.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shaoping Ji, shaopingji@henu.edu.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.